346 related articles for article (PubMed ID: 33236471)
1. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience.
Bonifati C; Morrone A; Cristaudo A; Graceffa D
Dermatol Ther; 2021 Jan; 34(1):e14584. PubMed ID: 33236471
[TBL] [Abstract][Full Text] [Related]
2. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
3. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
Mastorino L; Dapavo P; Susca S; Cariti C; Siliquini N; Verrone A; Stroppiana E; Ortoncelli M; Quaglino P; Ribero S
J Dtsch Dermatol Ges; 2024 Jan; 22(1):34-42. PubMed ID: 37926830
[TBL] [Abstract][Full Text] [Related]
4. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
5. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
6. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
7. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
8. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
Gargiulo L; Ibba L; Malagoli P; Balato A; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Megna M; Mercuri SR; Travaglini M; Costanzo A; Narcisi A
Front Immunol; 2023; 14():1341708. PubMed ID: 38274801
[TBL] [Abstract][Full Text] [Related]
9. Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort.
Viola R; Mastorino L; Megna M; Damiani G; Gisondi P; Argenziano G; Peris K; Prignano F; Burlando M; Conti A; Loconsole F; Malagoli P; Zalaudek I; Cacciapuoti S; Bellinato F; Balato A; De Simone C; Chersi K; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
Int J Dermatol; 2024 Mar; 63(3):351-358. PubMed ID: 38178802
[TBL] [Abstract][Full Text] [Related]
10. Novel Biologic Agents Targeting Interleukin-23 and Interleukin-17 for Moderate-to-Severe Psoriasis.
Chen Z; Gong Y; Shi Y
Clin Drug Investig; 2017 Oct; 37(10):891-899. PubMed ID: 28755058
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study.
Narcisi A; Valenti M; Cortese A; Toso F; Pavia G; Gargiulo L; Borroni R; Costanzo A
Dermatol Ther; 2022 Feb; 35(2):e15228. PubMed ID: 34820969
[TBL] [Abstract][Full Text] [Related]
13. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593
[TBL] [Abstract][Full Text] [Related]
14. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.
Prignano F; Pescitelli L; Trovato E; DI Cesare A; Cuccia A; Mazzatenta C; Pellegrino M; Marsili F; Castelli A; Brandini L; Niccoli MC; Taviti F; Ricceri F; Panduri S; Buggiani G; Ghilardi A; Rubegni P; Romanelli M; Pimpinelli N
Ital J Dermatol Venerol; 2022 Dec; 157(6):469-479. PubMed ID: 35785927
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
16. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Sano S; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 Feb; 50(2):e41-e68. PubMed ID: 36582113
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of emerging immunotherapies in psoriasis.
Yiu ZZ; Warren RB
Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
[TBL] [Abstract][Full Text] [Related]
18. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Yang K; Oak ASW; Elewski BE
Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA).
Graier T; Weger W; Jonak C; Sator P; Zikeli C; Prillinger K; Sassmann C; Gruber B; Saxinger W; Ratzinger G; Painsi C; Mlynek A; Häring N; Sadoghi B; Trattner H; Müllegger R; Quehenberger F; Salmhofer W; Wolf P
Sci Rep; 2022 Sep; 12(1):15078. PubMed ID: 36064563
[TBL] [Abstract][Full Text] [Related]
20. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]